The Imaging Features of Isocitrate Dehydrogenase Mutant Gliomas

Main Article Content

Fatima Mubarak

Abstract

To appraise Magnetic resonance imaging features of isocitrate dehydrogenase (IDH) mutant gliomas. In literature, IDH mutant gliomas are usually in frontal lobes, they are less contrast-enhancing with well-defined borders. They have high ADC values low regional cerebral blood volumes. 2-HG detection of MR spectroscopy has more promising results. 

In this review, we tried to describe conventional and advanced neuroimaging features of IDH mutant Gliomas.

Keywords:
Glioma, IDH, mutant, MRI, MR spectroscopy, MR perfusion.

Article Details

How to Cite
Mubarak, F. (2020). The Imaging Features of Isocitrate Dehydrogenase Mutant Gliomas. Journal of Advances in Medicine and Medical Research, 31(11), 1-4. https://doi.org/10.9734/jammr/2019/v31i1130334
Section
Review Article

References

Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016;131:803–820.

Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469–474.

Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015;372:2481–2498.

Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumours. N Engl J Med. 2015;372:2499–2508.

Zhou H, Vallieres M, Bai HX, et al. MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro Oncol. 2017;19:862–870

Zhang B, Chang K, Ramkissoon S, et al. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017;19:109– 117.

Yu J, Shi Z, Lian Y, et al. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma. Eur Radiol 2017;27:3509– 3522.

Xing Z, Yang X, She D, Lin Y, Zhang Y, Cao D. Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging. AJNR Am J Neuroradiol. 2017;38:1134–1144.

Tietze A, Choi C, Mickey B, et al. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. J Neurosurg. 2018;128:391–398.

Tan W, Xiong J, Huang W, Wu J, Zhan S, Geng D, Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI. J Magn Reson Imaging. 2017;45:492–499.

Stadlbauer A, Zimmermann M, Kitzwogerer M, et al. MR Imaging-derived oxygen metabolism and neovasculari-zation characterization for grading and IDH gene mutation detection of gliomas. Radiology. 2017;283:799–809.

Price SJ, Allinson K, Liu H, et al. Less invasive phenotype found in isocitrate dehydrogenase-mutated glioblastomas than in isocitrate dehydrogenase wild- type glioblastomas: A diffusion tensor imaging study. Radiology. 2017;283:215–221.

Patel SH, Poisson LM, Brat DJ, et al. T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: A TCGA/TCIA project. Clin Cancer Res. 2017;23:6078–6085.

Nakae S, Murayama K, Sasaki H, et al. Prediction of genetic subgroups in adult supratentorial gliomas by pre- and intraoperative parameters. J Neurooncol. 2017;131:403–412.

Lasocki A, Tsui A, Gaillard F, Tacey M, Drummond K, Stuckey S. Reliability of noncontrast-enhancing tumour as a biomarker of IDH1 mutation status in glioblastoma. J Clin Neurosci. 2017; 39:170–175.

Jiang S, Zou T, Eberhart CG, et al. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI. Magn Reson Med. 2017;78:1100–1109.

Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012;18: 624–629.

Li Z, Wang Y, Yu J, Guo Y, Cao W. Deep Learning-based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low-grade glioma. Sci Rep. 2017;7:5467.

Xiong J, Tan W, Wen J, et al. Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours. Eur Radiol. 2016;26:1705–1715.

Lasocki A, Tsui A, Gaillard F, Tacey M, Drummond K, Stuckey S. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma. J Clin Neurosci. 2017; 39:170–175.

Sonoda Y, Shibahara I, Kawaguchi T, et al. Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas. Brain Tumor Pathol. 2015;32:99–104.

Reyes-Botero G, Dehais C, Idbaih A, et al. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol. 2014;16:662–670.

Carrillo JA, Lai A, Nghiemphu PL, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012;33:1349–1355.

Delfanti RL, Piccioni DE, Handwerker J et al. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. J Neurooncol. 2017;135: 601–609.

Wang K, Wang Y, Fan X, et al. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients. Neuro Oncol. 2016;18:589–597.

Choi C, Raisanen JM, Ganji SK, et al. Prospective longitudinal analysis of 2-hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the management of patients with IDH-mutant glioma. J Clin Oncol. 2016;34: 4030–4039.

Wasserman JK, Nicholas G, Yaworski R, et al. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. PLoS One. 2015;10:e0123890.

Yamashita K, Hiwatashi A, Togao O et al (2MR imagingbased analysis of glioblastoma multiforme: Estimation of IDH1 mutation status. AJNR Am J Neuroradiol. 2016;37:58–65.

Leu K, Ott GA, Lai A, et al. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas. J Neurooncol. 2017; 134:177–188

Lee S, Choi SH, Ryoo I, et al. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neurooncol. 2015;121:141–150.

Tan W, Xiong J, Huang W, Wu J, Zhan S, Geng D, Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI. J Magn Reson Imaging. 2017;45:492–499.